38 2011 ACCF/AHA/HRS Guidelines Risk Category 1 Recommended Therapy No risk factorsAspirin, 81 to 325 mg daily One moderate risk factorAspirin, 81 to 325 mg daily, or warfarin (INR 2.0 to 3.0, target 2.5) Any high risk factor or > 1 moderate-risk factor Warfarin (INR 2.0 to 3.0, target 2.5)* Antithrombotic Therapy for Patients with Atrial Fibrillation 1.Fuster V.
{"Image DocumentName": "2011 ACCF/AHA/HRS Guidelines", "Image ImageDescription": "Antithrombotic Therapy for Patients with Atrial Fibrillation. Risk Category1. Recommended Therapy. No risk factors. Aspirin, 81 to 325 mg daily. One moderate risk factor. Aspirin, 81 to 325 mg daily, or warfarin (INR 2.0 to 3.0, target 2.5) Any high risk factor or. > 1 moderate-risk factor. Warfarin (INR 2.0 to 3.0, target 2.5)  Less Validated / Weaker Risk Factors1. Moderate Risk Factors. High Risk Factors. Female gender. Age >75 years. Previous stroke, TIA or embolism. Age 65 to 74 years. Hypertension. Mitral stenosis. Coronary artery disease. Heart failure. Prosthetic heart valve    If mechanical valve, target international normalized ratio (INR) > 2.5. Thyrotoxicosis. LV ejection fraction <35% Diabetes mellitus. Speaker Note: This slide is set up as an animated slide where each of the three sections appear by each mouse click. TABLE 13. Antithrombotic Therapy for Patients With Atrial Fibrillation. INR indicates international normalized ratio; LV, left ventricular; and TIA, transient ischemic attack. \u204e If mechanical valve, target international normalized ratio (INR) greater than 2.5. Circulation Mar 15;123(10):e Epub 2011 Mar ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Fuster V, Ryd\u00e9n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS,Kushner FG, Ohman EM, Stevenson WG, Tarkington LG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force. Collaborators (13) PMID: J Am Coll Cardiol Mar 15;57(11): Epub 2011 Feb ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM. Comment in Dabigatran in patients with nonvalvular atrial fibrillation. [J Am Coll Cardiol. 2011] PMID: Original text in 2011 Update had footnote to Connolly SJ, below: N Engl J Med Sep 17;361(12): Epub 2009 Aug 30. Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. PMID: Focused Update Recommendation Class I2. Comments. Dabigatran is useful as an alternative to warfarin for the prevention of stroke and systemic thromboembolism in patients with paroxysmal to permanent AF and risk factors for stroke or systemic embolization who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure (creatinine clearance <15 mL/min) or advanced liver disease (impaired baseline clotting function). (Level of Evidence: B) New Recommendation. Fuster V. Circulation Mar 15;123(10): Pub Med PMID: Wann LS, et al. J Am Coll Cardiol Mar 15;57(11): Pub Med PMID:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}